EBC - ON DEMAND
European Bifurcation Club 2014 – EBC 2014 – Bordeaux, France
At last randomized trials with dedicated bifurcation stents!
The Nile Dedicated Bifurcation Stent: Long-Term Results and Technology Advancement
Author: Gregory Pavlides, MD, PhD, Director, Cardiac Cath Labs & Interv Cardiology, University of Nebraska Medical Center, Omaha, NE, USA
CONCLUSION
- Preliminary results with the novel Nile SIRtechnology, incorporating the Nile dedicated bifurcation pladorm with a biodegradable PLA polymer as drug-carrier, and sirolimus as antiproliferative agent, demonstrated favorable results in the treatment of complex bifurcation lesions, including high angiographic and procedural success and safety
- Initial assessment of efficacy at 6 months follow-up showed high efficacy in inhibi-ng neoin-mal hyperplasia within the bifurcation anatomy, as demonstrated by the relatively low late lumen loss – a surrogate of neointimal hyperplasia, comparable to the current best- in-class “limus” devices
- Results from ongoing registry expected in order to confirm these promising results